Subreal is building a predictive layer for addiction medicine that combines regulated clinical software, a foundation model, and drug discovery. Its platform, Subreal-CARE, monitors neurological, physiological, and psychometric signals to detect relapse risk earlier than traditional self-reported assessments. The company targets opioid use disorder first, with plans to expand to alcohol and benzodiazepine use disorders.
Funding
Funding not disclosed
Founders
Product
Problem
Substance use disorders are chronic conditions where relapse is a common part of recovery, yet current monitoring tools rely on sporadic questionnaires and self-reported scales that miss moment-to-moment changes. These methods are prone to recall bias and long gaps between clinical contacts, meaning deterioration is often detected only after disengagement or crisis. With 40-60% of patients relapsing within a year of treatment discharge, the window for preventive intervention frequently closes before the next appointment.
Solution
Subreal is building a predictive layer for addiction medicine that spans data collection, modeling, and treatment across three integrated programs. Subreal-CARE is a regulated clinical software platform that captures continuous neurological, physiological, and psychometric signals from patients, creating a longitudinal record that feeds into Subreal-General, a foundation model for recovery. This model analyzes the aggregated data to identify early warning signs of relapse and deterioration, enabling clinicians to intervene before a crisis occurs. The insights generated also inform the company's discovery program, which aims to develop new medicines for addiction treatment. By connecting clinical deployment, model training, and therapeutic development, Subreal creates a feedback loop where each program strengthens the others.
Target Audience
Primary customers are addiction treatment providers, including clinics and healthcare systems, that need more reliable monitoring tools for substance use disorder patients, as well as pharmaceutical companies interested in developing new addiction treatments.
Features
- Regulated clinical software (Subreal-CARE) configured as a single platform for opioid, alcohol, and benzodiazepine use disorders
- Foundation model (RECOVERY-FM) trained on longitudinal patient data to predict relapse risk and treatment response
- Continuous monitoring of neurological, physiological, and psychometric signals rather than sporadic self-reported assessments
- Integration with UK addiction services and full medical-device conformity (Class IIb) as near-term milestones
- Primary focus on opioid use disorder, affecting approximately 40 million people globally, with secondary indications for alcohol and benzodiazepine use